Chelsea Therapeutics International (CHTP) 6.52

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Chelsea Therapeutics International (CHTP) 6.52 $CHTP

Uptrend Call Working As Chelsea Therapeutics International Stock Rises 29.6% (CHTP)
Comtex SmarTrend(R) - Fri Mar 20, 4:56PM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 14 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)

Chelsea Therapeutics International Up 29.6% Since SmarTrend Uptrend Call (CHTP)
Comtex SmarTrend(R) - Fri Mar 13, 11:36AM CDT
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 14 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)

29.6% Return Seen to Date on SmarTrend Chelsea Therapeutics International Call (CHTP)
Comtex SmarTrend(R) - Thu Feb 05, 11:03AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 13 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)

Shares of CHTP Up 29.6% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 31, 9:46AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 12 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)

Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014
M2 - Thu Dec 18, 3:29AM CST
Research and Markets (http://www.researchandmarkets.com/research/3j4lzn/attention_deficit) has announced the addition of the "Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics Companies Mentioned: - DURECT Corporation - Eli Lilly and Company - Dainippon Sumitomo Pharma - Taisho Pharmaceutical - NeuroDerm - Samyang Holdings Corporation - Pfizer - Impax Laboratories - Shire - Collegium Pharmaceutical - Bionomics Limited - Chelsea Therapeutics International - Hisamitsu Pharmaceutical - Theravance - Arbor Pharmaceuticals - Curemark - Supernus Pharmaceuticals - Intra-Cellular Therapies - Tris Pharma - Neos Therapeutics - KemPharm - Otsuka Holdings - Reviva Pharmaceuticals - Amarantus Bioscience Holdings - Mnemosyne Pharmaceuticals - Alcobra - Signature Therapeutics - P2D Bioscience - AbbVie For more information visit http://www.researchandmarkets.com/research/3j...on_deficit
IPXL: 46.34 (-0.47), CHTP: 6.52 (-0.03), SUPN: 11.35 (-0.11), ITCI: 27.64 (+1.30), LLY: 76.12 (+1.90), DRRX: 1.68 (-0.01)

Chelsea Therapeutics International Shares Up 29.6% Since SmarTrend's Buy Recommendation (CHTP)
Comtex SmarTrend(R) - Tue Dec 16, 5:06PM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 11 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)

Chelsea Therapeutics International Has Returned 29.6% Since SmarTrend Recommendation (CHTP)
Comtex SmarTrend(R) - Tue Dec 02, 9:43AM CST
SmarTrend identified an Uptrend for Chelsea Therapeutics International (NASDAQ:CHTP) on January 15th, 2014 at $5.03. In approximately 11 months, Chelsea Therapeutics International has returned 29.62% as of today's recent price of $6.52.
CHTP: 6.52 (-0.03)

Genervon ALS drug shows encouraging results
Seeking Alpha - at Seeking Alpha - Mon Oct 20, 7:27AM CDT

BIIB: 475.98 (+42.33), MNOV: 3.53 (-0.02), CHTP: 6.52 (-0.03), ADMS: 17.94 (-0.05), ACOR: 34.74 (-0.39), BCLI: 4.45 (+0.14), BSX: 17.84 (+0.03), IPXL: 46.34 (-0.47), AVNR: 16.96 (unch), ACAD: 34.45 (-0.54), CVTS: (), MRK: 58.58 (+0.37), TEVA: 62.10 (+0.55), PRTA: 38.66 (+9.43), PRAN: 1.15 (-0.08), FOLD: 11.61 (-0.85), CUR: 2.42 (+0.14)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

M&A Source's 2026 Conference Tackles Deal-Making Drama

Updated Category News Views 84

High Stakes and Deep Insights Await in Houston Cracking the nut of lower-middle market transactions ain’t a walk in the park. M&A Source®'s Fall 2026 Conference is gearing up to address the very dramas that lurk behind the scenes. Kicking off November 2-4 at the opulent JW Marriott in Houston, Texas, the event is looking to assemble a heavyweight lineup of...

Continue Reading
Co-Diagnostics Nearing India TB Test Launch By 2026

Updated Category News Views 98

Co-Diagnostics Gears Up for Indian TB Test Market Picture this: Co-Diagnostics, a molecular diagnostics player, is on the brink of a significant leap toward expanding its footprint in India with its TB test. The stage is set, with a clinical study already turning in results as solid as old boots. We're talking sensitivity hovering around 97.3% and specificity at...

Continue Reading
Tamara Toles O'Laughlin: Steering Philanthropy's Next Era

Updated Category News Views 52

Leadership Transition in Philanthropy Everyone knows the drill: leadership changes are often a toss-up. You could get a fresh burst of energy or spend years longing for the good old days. That's where The New York Women's Foundation finds itself as they hand over the reins from Ana L. Oliveira to Tamara Toles O'Laughlin. In a world where philanthropic shifts can either...

Continue Reading
Fairfax Crest: A New Chapter in Affordable Housing

Updated Category News Views 31

Setting the Stage: Fairfax Crest's Grand Opening You know what's better than leaving a dusty old car park underutilized? Turning it into homes for folks who really need them. That's exactly what went down in Fairfax County as they cut the ribbon on their latest affordable housing project, Fairfax Crest. We're talking 279 affordable units sprouting up where there once lay...

Continue Reading
Hisense's AI S7 Dishwasher Revolutionizes Home Living

Updated Category News Views 75

The Intersection of AI and Home Appliances In a world where families are looking for more efficiency, Hisense isn’t just tossing another dishwasher into the wild. No, they're aiming to redefine the whole damn experience of household chores with their latest brainchild, the Hisense S7 Dishwasher. Packed with AI smarts and an impressive tech bouquet, this bad boy is all...

Continue Reading
Personalis Merger Faces Investigation: $16.25 Offers Scrutinized

Updated Category News Views 38

Market Storm or Light Drizzle? When the sharks smell blood or the legal eagles start circling, you know something stinks. BFA Law is sniffing around, and it isn’t just for sport. They’re putting their magnifying glass on this curious $16.25 per share transaction where Tempus AI plans to gobble up Personalis lock, stock, and barrel. For investors holding NASDAQ:PSNL,...

Continue Reading
XCMG Climbs Fortune China 500: Strengthens Global Edge

Updated Category News Views 83

XCMG's Ascent on the Fortune China 500 When it comes to scaling new heights, XCMG Machinery is clearly in the driver's seat, roaring up the Fortune China 500 to claim the 202nd spot, leaping ten ranks from last year. While others may coast, XCMG's trajectory is anything but idle, retaining its crown among Chinese construction machinery titans. The recent summit in Chengdu...

Continue Reading
Common Thread Advisors: Transforming Change in Business

Updated Category News Views 41

Navigating the Storm of Change: A New Player in Town You know, just when you think you've got the business world figured out, something sharp comes along. Today, it’s Common Thread Advisors, making its grand entrance to help organizations steer through the dense fog of change. This isn’t your everyday, run-of-the-mill consultancy. No sir, they’re out here with a...

Continue Reading
Bybit’s Gold Yield Offer: 2.83% APR on XAUT

Updated Category News Views 74

Gold Savings with a Tokenized Twist Taking a wild swing at pairing gold and crypto in a digestible package, Bybit and the XAUE Protocol have teamed up to offer a 2.83% fixed APR on XAUT Savings. If you're itching for something that doesn’t make your stomach churn like some of the wild crypto rides, this just might soothe those nerves. Or maybe it’s just a slick way to...

Continue Reading
Fluence Faces Legal Battle Amid Major Stock Plunge

Updated Category News Views 55

The High Stakes for Fluence Energy Investors Well, here's a plot twist, or perhaps not for those who've been keeping an eye on the renewable energy sector. Fluence Energy (NASDAQ:FLNC), a supposed heavyweight in energy storage and renewable innovations, is tangled in a legal web over securities fraud. As of now, Fluence has been slapped with a class action lawsuit...

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Safety Monitoring with LifeSphere Advanced Signals

Updated Category News Views 244

Revolutionizing Pharmacovigilance with AI In the realm of life sciences, ensuring patient safety is paramount. Recently, a prominent pharmaceutical organization announced its partnership with ArisGlobal in implementing the innovative LifeSphere Advanced Signals. This advanced pharmacovigilance solution utilizes automation and AI-driven insights to enhance signal detection...

Continue Reading
Arcellx Inc. Under Fire: Shareholder Concerns Mounting Fast

Updated Category News Views 163

What's Going Down with Arcellx? Kickin’ off with the news—Arcellx Inc. (NASDAQ: ACLX) is under the microscope for potential shareholder shenanigans. I mean, there’s chatter coming from the Ademi Firm, pointing fingers at the board for not playing fair with the shareholders. Not exactly a good look, right? This takes me back to times when I’ve seen boards pulling...

Continue Reading
Memecoins Rally: The Strategic Advantage of Investing in PEPE

Updated Category News Views 164

The Surge of Pepe and Shiba Inu in Recent Days In a surprising turn of events, the memecoins Pepe and Shiba Inu have experienced remarkable gains amidst a largely negative market atmosphere. While the broader cryptocurrency market has been facing some challenges, these two coins have struck a positive chord with traders and investors alike. Market Performance: Gains...

Continue Reading
Transforming the Electrical Grid: Lessons from Advanced Technologies

Updated Category News Views 176

Modernizing the Electrical Grid: An Urgent Need As the demand for energy continues to increase, the necessity for a robust and efficient electrical grid becomes increasingly evident. States across the nation are actively seeking solutions to modernize their utilities and ensure a reliable energy supply. One of the most promising approaches involves the implementation of...

Continue Reading
WEX Inc. CFO's Recent Stock Sale: Implications for Investors

Updated Category News Views 122

WEX Inc. CFO's Notable Stock Sale WEX Inc. (NYSE: WEX) Chief Financial Officer Jagtar Narula recently made headlines by selling 508 shares of the company's stock. Priced at $200 each, this sale totaled an impressive $101,600. Transactions of this magnitude naturally attract attention from both investors and market analysts. Context Behind the Sale The sale occurred under...

Continue Reading